Jubilant Pharmova's subsidiary received tentative USFDA approval for Pantoprazole Sodium oral suspension. Commercial launch awaits patent expiry in December 2026.
Jubilant Pharmova Secures USFDA Tentative Approval for Pantoprazole Sodium Suspension
Jubilant Pharmova Ltd. has received tentative approval from the United States Food and Drug Administration (USFDA) for its Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet. This approval was communicated on June 25, 2026, and is for Jubilant Generics Limited, a subsidiary of Jubilant Pharma Limited. ## What just happened The USFDA has granted tentative approval for Pantoprazole Sodium Delayed Release Oral Suspension. This marks a significant regulatory step for the company's generics business. ## Why this matters This approval signals the readiness of Jubilant Pharmova's Roorkee facility for the US market and progresses its pipeline. It validates their manufacturing compliance and regulatory adherence. ## The backstory The approval is linked to the company's Solid Dosage Manufacturing Facility in Roorkee, which successfully passed a pre-approval inspection (PAI) by the USFDA on August 2, 2025. This inspection confirmed the facility's compliance with US regulatory standards. ## What changes now While this is a tentative approval, it paves the way for commercial launch. The actual market entry is scheduled after the patent expiry of the Reference Listed Drug (RLD), anticipated in December 2026. ## Risks to watch The primary risk is the dependency on the RLD patent expiry. Any delays or unforeseen regulatory hurdles post-patent expiration could impact the commercialization timeline. ## Peer comparison Jubilant Pharmova operates in the generics pharmaceutical sector, which is highly competitive. Companies often seek USFDA approvals to expand their market reach and revenue streams. Success in clearing USFDA inspections is a key differentiator. ## Context metrics (time-bound) - USFDA communication date: June 25, 2026 - Roorkee facility PAI completion: August 2, 2025 - RLD patent expiry: Expected December 2026 ## What to track next Investors should monitor the company's progress towards final approval post-patent expiry and any updates on the commercial launch strategy for Pantoprazole Sodium.
Disclaimer:This article is published for informational purposes only. While reasonable efforts are made to ensure accuracy, completeness, and timeliness, readers are encouraged to independently verify information before making any decisions based on the content. The views and information presented are subject to editorial review and may be updated without notice.
